Drug Profile


Alternative Names: Gamma-Methylene-10-deazaminopterin; L-gamma-Methylene-10-deazaminopterin; MDAM

Latest Information Update: 01 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of South Alabama
  • Developer BioNumerik Pharmaceuticals
  • Class
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 May 2007 This programme is still in active development
  • 26 Jun 2000 A phase I study in patients with solid tumours has been added to the therapeutic trials, adverse events and pharmacokinetics sections
  • 02 Jul 1998 Phase-I clinical trials for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top